Roche secures rights to Alector's Parkinson's therapy for up to $1.27 billions, Alector shares surge
路透社2026/10/05 12:16Reuters, October 5 – U.S. biotechnology company Alector announced on Monday that Swiss pharmaceutical giant Roche will pay up to 1.27 billion dollars to obtain licensing rights for its experimental Parkinson's disease therapy. Boosted by this news, Alector’s shares surged 72% in pre-market trading. Genentech, a subsidiary of Roche, will pay Alector a 100 million dollar upfront payment, with an additional payment of up to 1.17 billion dollars if the therapy meets certain developmental, regulatory, and sales milestones. Alector will also receive royalty payments. Specific details are as follows: the agreement grants Genentech exclusive global rights to develop, produce, and commercialize AL050, an experimental therapy targeting enzyme deficiency associated with Parkinson’s disease. Genentech will be responsible for the development, regulatory filings, production, and commercialization of the therapy. AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency—which leads to the buildup of certain fats and increases the risk of Parkinson’s. This deal is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline. In June, Roche and Nurix Therapeutics entered into a licensing and collaboration agreement involving a blood cancer medication, with a deal value of up to 2.3 billion dollars.
Reuters, October 5 - US biotechnology company Alector announced on Monday that Swiss pharmaceutical company Roche ROPC.S will pay up to $1.27 billion to acquire the rights to its experimental Parkinson's disease therapy ALEC.O, boosting the company's share price by 72% in pre-market trading.
Roche's subsidiary Genentech will pay Alector an upfront payment of $100 million, and if the therapy meets research, regulatory, and sales targets, an additional payment of up to $1.17 billion will be made. Alector will also receive royalty payments.
Details are as follows:
The agreement grants Genentech exclusive global rights to develop, manufacture, and sell AL050, an experimental therapy aimed at addressing enzyme deficiency associated with Parkinson's disease.
Genentech will be responsible for the development, regulatory filings, manufacturing, and commercialization of the therapy.
AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency — this deficiency can lead to the accumulation of certain fats and increase the risk of Parkinson's disease.
This transaction is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline.
In June this year, Roche and Nurix Therapeutics NRIX.O entered into a licensing and collaboration agreement (link) involving a blood cancer drug, with a transaction value of up to $2.3 billion.
(For the convenience of non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translations may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of the automated translation text, and provides it solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Sector Update: Financial Stocks Advance Pre-Bell Monday
09:26 AM EDT, 10/05/2026 (MT Newswires) -- Financial stocks were advancing pre-bell Monday, with the State Street Financial Select Sector SPDR ETF (XLF) 0.2% higher. The Direxion Daily Financial Bull 3X Shares (FAS) was up 0.6% and its bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was 0.3% lower. UBS (UBS) had engaged with Nordea Bank over exiting Switzerland or potentially facing a new law that could compel it to hold up to $16 billion in additional equity or CET1 capital, Bloomberg reported, citing unnamed people familiar with the matter. UBS Group stock was up 0.6% premarket. Intercontinental Exchange (ICE) shares were up more than 1% after the company said it launched new tanker and container freight futures and options as average daily volume across its freight markets rose 33% year to date. Ares Management (ARES) is seeking a multi-million-pound upfront payment from BT Group in exchange for supporting a potential takeover of struggling broadband provider TalkTalk, as the company faces a possible administration filing, Sky News reported. Ares Management stock was 0.5% lower pre-bell.
Zacatecas Silver Secures Option to Acquire Lourdes Project in Mexico
09:26 AM EDT, 10/05/2026 (MT Newswires) -- Zacatecas Silver (ZAC.V) secured an option to acquire the Lourdes gold-silver project in Mexico from Guanajuato Silver (GSVR.V), it said Monday. Under the terms, Zacatecas Silver must pay $825,000 in cash and shares over two years, with no minimum exploration expenditure commitments, the company said. Zacatecas Silver will also grant a 2.0% net smelter royalty (NSR), which can be halved for $1 million. The project also includes an existing 3.0% NSR, of which 2.0% may be bought back for $2 million, the company said. Zacatecas shares last traded Thursday, closing at CA$0.055 on the TSX Venture Exchange.
Neighborhood Intelligence prices registered direct offering at $45.5 million
Neighborhood Intelligence set a registered direct offering of 16,485,508 common shares or pre-funded warrants at $2.76 each. Gross proceeds expected at about $45.5 million; closing targeted on or about Oct. 6, 2026. Warrants issued to buy up to 16,123,189 shares at $3.45; exercisable in six months; expire five years later. Highbridge led the deal; management participated, including Marcus Lemonis; CEO to buy shares only without warrants. Net proceeds earmarked to accelerate merger synergies, build inventory, support working capital; at-the-market facility cut to about $75 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neighborhood Intelligence Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261005545003) on October 05, 2026, and is solely responsible for the information contained therein.
Chevron names Jeff Gustavson CFO in senior leadership reshuffle
Chevron set senior leadership changes effective Jan. 1, 2027, reshaping strategy, finance, Oil, Products & Gas, New Energies. Mark Nelson shifts from executive vice president of Oil, Products & Gas to lead Strategy and Business Development. Eimear Bonner moves from chief financial officer to president, Oil, Products & Gas. Jeff Gustavson becomes chief financial officer, moving from president of New Energies. Brent Gros takes over New Energies, moving from president of Offshore, adding oversight of Chevron’s AI strategy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chevron Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261005366851) on October 05, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
